Book contents
- Frontmatter
- Contents
- Acknowledgments
- Foreword
- Introduction
- 1 Gifts from the Pharmaceutical Industry to Physicians: Do They Influence your Prescribing?
- 2 Ethical Considerations of Receiving Gifts from the Pharmaceutical Industry
- 3 One on One: An Analysis of the Physician–Pharmaceutical Company Representative (PCR) Detailing Interaction
- 4 Medical Academia and the Pharmaceutical Industry
- 5 Teaching Physicians in Training about Pharmaceutical Industry Promotion
- 6 Continuing Medical Education: How to Separate Continuing Medical Education from Pharmaceutical Industry Promotion
- 7 Professional Policies on Physician–Pharmaceutical Industry Interaction (PPII)
- 8 Preserving Professionalism: Patients' Perceptions of Physicians' Acceptance of Gifts from the Pharmaceutical Industry
- 9 To Sample or Not to Sample? The Use of Pharmaceutical Industry–Supplied Medications in Medical Practice
- 10 Physician–Pharmaceutical Industry Interactions (PPIIs), the Law and the Media
- 11 Direct-to-Consumer Advertising (DTCA)
- 12 Pharmaceutical Industry Interactions with Health Care Professionals: A Global Perspective
- 13 Internet Resources for Teaching about PPII and Independent Sources of Information about Prescription Medicines
- Appendix I
- Appendix II
- Index
- References
7 - Professional Policies on Physician–Pharmaceutical Industry Interaction (PPII)
Published online by Cambridge University Press: 03 March 2010
Book contents
- Frontmatter
- Contents
- Acknowledgments
- Foreword
- Introduction
- 1 Gifts from the Pharmaceutical Industry to Physicians: Do They Influence your Prescribing?
- 2 Ethical Considerations of Receiving Gifts from the Pharmaceutical Industry
- 3 One on One: An Analysis of the Physician–Pharmaceutical Company Representative (PCR) Detailing Interaction
- 4 Medical Academia and the Pharmaceutical Industry
- 5 Teaching Physicians in Training about Pharmaceutical Industry Promotion
- 6 Continuing Medical Education: How to Separate Continuing Medical Education from Pharmaceutical Industry Promotion
- 7 Professional Policies on Physician–Pharmaceutical Industry Interaction (PPII)
- 8 Preserving Professionalism: Patients' Perceptions of Physicians' Acceptance of Gifts from the Pharmaceutical Industry
- 9 To Sample or Not to Sample? The Use of Pharmaceutical Industry–Supplied Medications in Medical Practice
- 10 Physician–Pharmaceutical Industry Interactions (PPIIs), the Law and the Media
- 11 Direct-to-Consumer Advertising (DTCA)
- 12 Pharmaceutical Industry Interactions with Health Care Professionals: A Global Perspective
- 13 Internet Resources for Teaching about PPII and Independent Sources of Information about Prescription Medicines
- Appendix I
- Appendix II
- Index
- References
Summary
In recent decades many professional organizations have produced ethical guidelines or position statements on PPII. These documents cover many areas of interactions, from accepting gifts or continuing medical education (CME) support to conducting ethical research collaborations.
The American Medical Association (AMA) responded to public concerns regarding PPII in the 1980's with a code of medical ethics recommending that gifts to physicians should benefit patients, relate to the physician's work and be of minimal value.
Concern about increases in pharmaceutical industry (PI) promotion in training settings led to a 2002 position paper from the Accreditation Committee for Graduate Medical Education (ACGME) that emphasized the need to separate medical education from PI promotion.
The Accreditation Council for Continuing Medical Education (ACCME) has six standards for commercial support of CME activities.
The Association of American Medical Colleges has issued a publication in 2 parts titled Protecting Subjects, Preserving Trust and Promoting Progress.
The evidence of PI influence on medicine and the ensuing concern for professional integrity and patient care resulted in the American College of Physicians – American Society of Internal Medicine producing two ethical position papers. Both papers cover PI gifts to physicians; PI influence on medical education; academic and industry collaboration; and influence on medical professional societies.
In 1994 the Canadian Medical Association published a position paper, “Physicians and the Pharmaceutical Industry.” Guidelines were developed by the CMA to assist physicians in determining when a relationship with industry is appropriate.
Information
- Type
- Chapter
- Information
- Understanding Physician-Pharmaceutical Industry InteractionsA Concise Guide, pp. 36 - 39Publisher: Cambridge University PressPrint publication year: 2007
References
American Medical Association Council on Ethical and Judicial Affairs. Opinion 8.061: Gifts to -physicians from industry. Available at: http://www.ama-assn.org/ama/pub/category/4001.html (last accessed June 2006)
Principles to guide the relationship between graduate medical education and industry. Available at: http://www.acgme.org (under GME information; under position papers) (last accessed June 2006). ACGME, 2002
http://www.accme.org “Ask ACCME” http://www.accme.org/index.cfm/fa/faq.home/Faq.cfm Refer to the six standards of commercial support. Last accessed 12/2006
AAMC Task Force on Financial Conflicts of Interest in Clinical Research. Protecting subjects, preserving trust, promoting progress: Policy and guidelines for the oversight of individual financial interests in human subjects research. Association of American Medical Colleges, 2001. Available at: www.aamc.org/research/coi/start.htm (last accessed June 2006)
AAMC Task Force on Financial Conflicts of Interest in Clinical Research. Protecting subjects, preserving trust, promoting progress II: Principles and recommendations for oversight of an institution's financial interests in human subjects research. Association of American Medical Colleges, 2002. Available at: www.aamc.org/research/coi/start.htm (last accessed June 2006)
. Physician–industry relations, part 1: Individual physicians. Ann Intern Med 2002; 136(5):396–402CrossRefGoogle ScholarPubMed
. Physician–industry relations, part 2: Organizational issues. Ann Intern Med 2002; 136(5):403–6CrossRefGoogle Scholar
CMA Policy Summary. Physiciansand the pharmaceutical industry. CMAJ 1994; 150:256A–C. Available at: http://www.cma.ca (under policy/advocacy; under CMA policy base) (last accessed June 2006)
, , , , . Using the literature in developing McGill's guidelines for interactions between residents and the pharmaceutical industry. Acad Med 2004; 79(11):1033–40CrossRefGoogle ScholarPubMed
Whal D S, American Psychiatric Association Ethics Committee. Ethics Primer of the American Psychiatric Association. APA, 2001
American College of Obstetricians and Gynecologists. Guidelines for relationships with industry. Obstet Gynecol 2001; 98(4):703–6CrossRef
. Policies to regulate gifts to physicians from industry. JAMA 2003; 290:1776CrossRefGoogle ScholarPubMed
. How to dance with porcupines: Rules and guidelines on doctors' relations with drug companies. BMJ 2003 Aug 9; 327(7410):341Google Scholar
Code for interactions with health care professionals) http://www.phrma.org/code_on_interactions_with_healthcare_professionals/ Last accessed 12/2006
American Academy of Pharmaceutical Physicians. Code of ethics. Available at: www.aapp.org/ethics.php (last accessed June 2006)
Office of Inspector General. Compliance Program Guidance for Pharmaceutical Manufacturers. Available at: www.oig.hhs.gov/fraud/complianceguidance.html (last accessed June 2006)
American Medical Association. Interactions with pharmaceutical industry representatives. Available at: http://www.ama-assn.org/ama/pub/category/11910.html (last accessed June 2006)
. Psychiatric training program engagement with the pharmaceutical industry: An educational issue, not strictly an ethical one. Acad Psychiatry 2005; 29(2):215–21CrossRefGoogle Scholar
Accessibility standard: Unknown
Why this information is here
This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.Accessibility Information
Accessibility compliance for the PDF of this chapter is currently unknown
and may be updated in the future.